21 May 2013
Keywords: Nitto Denko, Quark Pharma, siRNA, Anti-fibrotic drug
Article | 16 July 2010
Japanese diversified materials manufacturer Nitto Denko and Quark Pharmaceuticals, a US firm specializing in the discovery and development of RNAi-based ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 July 2010
15 July 2010
20 May 2013
© 2013 thepharmaletter.com